Transcatheter Pulmonary Valve Implantation with the Alterra Adaptive Prestent, SAPIEN 3 Transcatheter Heart Valve and Pulmonary Delivery System: Two-year Pooled Outcomes of the ALTERRA trial

V. Vivian Dimas, MD, MBA, Shabana Shahanavaz, MBBS, MD, Daniel Balzer, MD, Gareth Morgan, MD, D. Scott Lim, MD, Aimee Armstrong, MD, Darren Berman, MD, Vasilis Babaliaros, MD, Dennis Kim, MD, PhD, Matthew Gillespie, MD, Alejandro Torres, MD, Robert Sommer, MD, Jamil Aboulhosn, MD, Thomas Jones, MD, Vaikom S. Mahadevan, MD, Gary Stapleton, MD, Xiao Yu, PhD, Girish Shirali, MBBS, MD, Anitha Parthiban, MD, Philipp Blanke, MD, Jonathon Leipsic, MD and Evan Zahn, MD

PICS | San Diego | September 4th, 2024

ALTERRA

Disclosure Information

Vivian Dimas, MD, MBA

As a faculty member for this program, I disclose the following relationships with industry:

- Consultant: Abbott Laboratories, Gore
- Paid Consultant and Proctor: B. Braun, Edwards Lifesciences, Medtronic

ALTERRA

ALTERRA Trial: Devices

Alterra Adaptive Prestent



Symmetric design

Alterra Delivery System

Commander Delivery System (Main Cohort)



Pulmonic Delivery System (PDS+CAP)

Tapered tip to facilitate crossing right-heart structures



ALTERRA Pivotal Trial: Study Design



Subject Accountability: Pooled Cohort



*Unsuitable/borderline anatomy
#All deaths adjudicated by the CEC
†Septic shock due to aspiration pneumonia

ALTERRA

Baseline Characteristics Pooled Cohort

Characteristic, mean ± SD or % (n)	Enrolled N=121
Age, years	28.6 ± 15.9
< 21 years	49%
Weight, kg	72.5 ± 21.7
Primary CHD Diagnosis	
Tetralogy of Fallot	66.1 % (80)
Pulmonary valve stenosis	27.3 % (33)
Pulmonary atresia	3.3% (4)
Other	3.3% (4)

All-cause Mortality



VI population
CEC adjudicated

ALTERRA

Perforation or Erosion



VI population
CEC adjudicated using VARC-2 definition

ALTERRA

Additional Outcomes

Incidence Rate, % (N patients) Valve Implanted Population	0 - 2 Years N=118
All-cause mortality	1.7% (2)
Cardiovascular deaths	0.8% (1)
RVOT reintervention	1.7% (2)
Transient pericardial effusion	0.8% (1)
Coronary artery compression	0%
Endocarditis	0%
Prestent thrombus	4.2% (5)
SAPIEN 3 valve thrombus	0.8% (1)

CEC Adjudicated Arrhythmias

Incidence Rate, % (n, N) or n events Valve Implanted Population	0 - 30 Days N=118	31 Days - 2 Years N=117
Arrhythmias	**37.3% (50, 44)**	**1.8% (2, 2)**
Ventricular tachycardia	19	0
NSVT	18	0
PVCs	18	1
Atrial fibrillation/flutter	4	0
Ventricular fibrillation	0	1
Other	9	0

Mean RVOT Gradient



Mean ± SE

VI population
Core Lab TTE

ALTERRA

Total Pulmonic Regurgitation



VI population
Core Lab TTE

ALTERRA

Total Pulmonic Regurgitation



100 % of patients had improved PR from baseline at all time points

VI population
Core Lab TTE

ALTERRA

Tricuspid Regurgitation



VI population
Core Lab TTE

ALTERRA

NYHA Class


p<0.0001
p<0.0001
p<0.0001
p<0.0001
100%
100%
98.1%
99.0%
% Patients
100
50
0
45.3%
43.6%
11.1%
87.2%
12.8%
86.1%
13.9%
84.1%
14.0%
91.3%
7.7%
1.9%
1.0%
Class I
Class II
Class III
Baseline (N=117)
30 days (N=117)
6 months (N=115)
1 year (N=107)
2 years (N=104)
Paired t-test for improvement from baseline
ALTERRA

Quality of Life



SF36 was assessed out to 1Y

Conclusions

The Alterra Adaptive Prestent/SAPIEN 3 system demonstrated safety and effectiveness out to 2 years:

- Excellent valve performance
  - 100% patients had improved PR from baseline (92.4% with ≤ mild PR)
  - Mean gradient remains stable
- Low rate of reintervention (1.8%)
- Ventricular arrhythmias were predominantly periprocedural and resolved
- Sustained improvement in NYHA class and QOL score
- No acute perforations or chronic erosions

ALTERRA

Thanks and Recognition

Participating Sites

St. Louis Children's Hospital, MO
Shabana Shahanavaz*, David Balzer

Cedars-Sinai Medical Center, CA
Evan Zahn, Ruchira Garg

Children's Health Dallas, TX
Vivian Dimas†

Emory University, GA
Vasilis Babaliaros, Dennis Kim

Children's Hospital Colorado, CO
Gareth Morgan

University of Virginia, VA
Scott Lim

Seattle Children's Hospital, WA
Thomas Jones

Nationwide Children's Hospital, OH
Aimee Armstrong

Children's Hospital of Philadelphia, PA
Matthew Gillespie

University of California, San Francisco, CA
Vaikom Mahadevan, Phillip Moore

Columbia University Medical Center
Alejandro Torres, Robert Sommer

Participating Sites

University of California, Los Angeles, CA
Jamil Aboulhosn

Cincinnati Children's Hospital
Shabana Shahanavaz

Texas Children's Hospital
Gary Stapleton †

Data & Safety Monitoring Board

Cardiovascular Research Foundation, New York, NY

Clinical Events Committee

Cardiovascular Research Foundation, New York, NY

CT Core Laboratory

St. Paul's Hospital, Vancouver, Canada
Directors: Jonathon Leipsic, Philipp Blanke

Echocardiographic Core Laboratory

Children's Mercy, Kansas City, MO
Directors: Girish Shirali, Anitha Parthiban‡

Sponsor

Edwards Lifesciences, Irvine, CA

*Dr. Shahanavaz is now with Cincinnati Children's Hospital, OH
†Dr. Dimas and Dr Stapleton are now with Medical City Children's Hospital Heart Center, TX
‡Dr. Parthiban is now with Texas Children's Hospital, Baylor College of Medicine, TX

Important Safety Information

Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent

Indications: The Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation as measured by echocardiography who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement.

Contraindications: The Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent is contraindicated in patients who cannot tolerate an anticoagulation/antiplatelet regimen or who have active bacterial endocarditis or other active infections.

Warnings: The devices are designed, intended, and distributed for single use only. **Do not resterilize or reuse the devices.** There are no data to support the sterility, nonpyrogenicity, and functionality of the devices after reprocessing. The physician must verify correct orientation of the valve prior to its implantation; the inflow (outer skirt end) of the valve should be oriented towards the proximal end (handle) of the delivery system to prevent the risk of severe patient harm. Prior to delivery, the valve must remain hydrated at all times and cannot be exposed to solutions other than its shipping storage solution and sterile physiologic rinsing solution. Valve leaflets mishandled or damaged during any part of the procedure will require replacement of the valve. Do not use the valve if the tamper evident seal is broken, the storage solution does not completely cover the valve, the temperature indicator has been activated, the valve is damaged, or the expiration date has elapsed. Do not mishandle the delivery system or use it if the packaging or any components are not sterile, have been opened or are damaged (e.g., kinked or stretched), or the expiration date has elapsed. Do not add or apply antibiotics to the storage solution, rinse solutions or to the valve.

Precautions: Long-term durability has not been established for the device. Regular medical follow-up is advised to evaluate device performance. Patients with hypersensitivities to cobalt, nickel, chromium, molybdenum, titanium, manganese, silicon, and/or polymeric materials may have an allergic reaction to these materials. Accelerated deterioration of the valve may occur in patients with an altered calcium metabolism. Assessment for coronary compression risk prior to implantation is recommended. Patient venous anatomy should be evaluated to prevent the risk of access that would preclude the delivery and deployment of the device. Use of excessive contrast media may lead to renal failure. Measure the patient's creatinine level prior to the procedure. Contrast media usage should be monitored. Fluoroscopically guided procedures are associated with a risk of radiation injury to the skin. Patient radiation dose should be monitored during the procedure. Glutaraldehyde may cause irritation of the skin, eyes, nose and throat. Avoid prolonged or repeated exposure to, or breathing of, the solution. Use only with adequate ventilation. If skin contact occurs, immediately flush the affected area with water; in the event of contact with eyes, seek immediate medical attention. For more information about glutaraldehyde exposure, refer to the Material Safety Data Sheet available from Edwards Lifesciences. Patient should be heparinized to maintain the ACT at ≥ 250 sec prior to introduction of the delivery system in order to prevent thrombosis. To maintain proper valve leaflet coaptation, do not overinflate the deployment balloon. Device recipients should be maintained on anticoagulant/antiplatelet therapy, except when contraindicated, as determined by their physician. This device has not been tested for use without antiplatelet therapy. It is recommended that all device recipients be prophylactically treated for endocarditis to minimize the possibility of prosthetic valve infection. Correct sizing of the prestent into the RVOT is essential to minimize risks such as paravalvular leak, migration, embolization, and/or RVOT rupture. If a prestent fracture is detected with significant loss in valve functionality, reintervention should be considered. Safety and effectiveness have not been established for patients with the following characteristics/comorbidities: blood dyscrasias defined as: leukopenia, acute anemia, thrombocytopenia, or history of bleeding diathesis or coagulopathy; a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid™), or clopidogrel (Plavix™), or sensitivity to contrast media, which cannot be adequately premedicated; positive urine or serum pregnancy test in female patients of child- bearing potential.

Potential Adverse Events: Potential risks associated with the anesthesia, interventional procedure, and imaging include but are not limited to death; stroke/transient ischemic attack; respiratory insufficiency or respiratory failure; cardiovascular or vascular injury, such as perforation or damage (dissection) of vessels, myocardium, or valvular structures, including rupture of the RVOT that may require intervention; pericardial effusion/cardiac tamponade; cardiac failure; embolic event: air, calcific material, thrombus, device fragments; infection, including incisional site infection, septicemia, and endocarditis; myocardial infarction; renal insufficiency or renal failure; conduction system injury; arrhythmia; deep vein thrombosis; arteriovenous (AV) fistula; systemic or peripheral nerve injury; systemic or peripheral ischemia; pulmonary edema; pneumothorax; pleural effusion; dyspnea; atelectasis; dislodgement of previously implanted devices (i.e. pacing lead); blood loss requiring transfusion; anemia; radiation injury; electrolyte imbalance; hypertension or hypotension; allergic reaction to anesthesia, contrast media, antithrombotic therapy, device materials; hematoma or ecchymosis; syncope; pain; exercise intolerance or weakness; inflammation; angina; fever. Potential risks, that may or may not require intervention, associated with the valve, prestent, delivery system, and/or accessories include, but may not be limited to, the following: cardiac arrest; cardiogenic shock; coronary flow obstruction/transvalvular flow disturbance; device thrombosis; injury to tricuspid valve; device fracture; device embolization; device acute migration or malposition; endocarditis; chest pain/discomfort; hemolysis/hemolytic anemia; device penetration/perforation into surrounding vasculature; device dysfunction (regurgitation and/or stenosis); aortic root distortion; embolic events: device fragments; mechanical failure of delivery system, and/or accessories.

Important Safety Information (continued)

Edwards Crimper

Indications: The Edwards crimper is indicated for use in preparing the Edwards SAPIEN 3 Ultra transcatheter heart valve and the Edwards SAPIEN 3 transcatheter heart valve, for implantation.

Contraindications: There are no known contraindications.

Warnings: The device is designed, intended, and distributed for single use only. **Do not resterilize or reuse the device.** There are no data to support the sterility, nonpyrogenicity, and functionality of the device after reprocessing. Do not mishandle the device. Do not use the device if the packaging or any components are not sterile, have been opened or damaged, or the expiration date has elapsed.

Precautions: For special considerations associated with the use of the Edwards crimper prior to THV implantation, refer to the THV Instructions for Use.

Potential Adverse Events: There are no known potential adverse events associated with the Edwards crimper.

CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician.

PP--US-10288 v1.0